1.14
+0.01(+0.88%)
Currency In USD
| Previous Close | 1.13 |
| Open | 1.14 |
| Day High | 1.15 |
| Day Low | 1.11 |
| 52-Week High | 4.19 |
| 52-Week Low | 0.97 |
| Volume | 132,139 |
| Average Volume | 3.04M |
| Market Cap | 12.27M |
| PE | -0.53 |
| EPS | -2.15 |
| Moving Average 50 Days | 1.21 |
| Moving Average 200 Days | 1.93 |
| Change | 0.01 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0.01 as of January 18, 2026 at a share price of $1.14. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $3.52 as of January 18, 2026 at a share price of $1.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
Newsfile
Jan 15, 2026 1:45 PM GMT
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developi
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Newsfile
Dec 23, 2025 1:45 PM GMT
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical comp
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
Newsfile
Nov 25, 2025 4:30 PM GMT
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to el